Privileged multi-target directed propargyl-tacrines combining cholinesterase and monoamine oxidase inhibition activities

Autor: Zofia Chrienova, Eugenie Nepovimova, Rudolf Andrys, Rafael Dolezal, Jana Janockova, Lubica Muckova, Lenka Fabova, Ondrej Soukup, Patrik Oleksak, Martin Valis, Jan Korabecny, José Marco-Contelles, Kamil Kuca

Publikováno v: Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 37, Iss 1, Pp 2605-2620 (2022)

Twenty-four novel compounds bearing tetrahydroacridine and N-propargyl moieties have been designed, synthesised, and evaluated in vitro for their anti-cholinesterase and anti-monoamine oxidase activities. Propargyltacrine 23 (IC50 = 21 nM) was the mo

Externí odkaz: https://doaj.org/article/1b4b604d4ed2463eadfec515d42a5564

Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects

Autor: Ícaro Durante, Rafael G. dos Santos, José C. Bouso, Jaime E. Hallak

Publikováno v: Brazilian Journal of Psychiatry, Vol 43, Iss 4, Pp 362-369 (2020)

Objective: Whether for spiritual, recreational, or potential therapeutic use, interest in ayahuasca has grown remarkably. Ayahuasca’s main active substances are N,N‐dimethyltryptamine and certain monoamine oxidase inhibitor β-carbolines. Possibl

Externí odkaz: https://doaj.org/article/bedc9ca4f0424f17a2b1c1cb252437a6

MAOI Antidepressants: Could They Be a Next-Generation ICB Therapy?

Autor: James Brown, Bo Li, Lili Yang

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

Externí odkaz: https://doaj.org/article/a10fd1ba87794f2683f55948680942ed

Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors

Autor: Nisha Abdul Rehuman, Jong Min Oh, Mohamed A. Abdelgawad, Eman A. M. Beshr, Mohammed A. S. Abourehab, Nicola Gambacorta, Orazio Nicolotti, Rakesh Kumar Jat, Hoon Kim, Bijo Mathew

Publikováno v: Pharmaceuticals, Vol 15, Iss 9, p 1152 (2022)

Two series of dimethoxy-halogenated chalcones (DM1–DM20) were synthesized and tested for their ability to inhibit monoamine oxidase (MAOs). Compound DM2 exhibited the most significant inhibition against MAO-B with an IC50 value of 0.067 µM, follow

Externí odkaz: https://doaj.org/article/d48fd536309740418ade16b8389df522

Efficacy and safety of selegiline across different psychiatric disorders

Autor: Flavia Rossano, Claudio Caiazza, Andrea Sobrino, Niccolò Solini, Alessandro Vellucci, Nicolas Zotti, Michele Fornaro, Ken Gillman, Carlo Ignazio Cattaneo, Vincent Van den Eynde, Tom K. Birkenhager, Henricus G. Ruhé, Stephen Stahl, Felice Iasevoli, Andrea de Bartolomeis

Publikováno v: European Neuropsychopharmacology, 72, 60-78. Elsevier
European neuropsychopharmacology
Rossano, F, Caiazza, C, Sobrino, A, Solini, N, Vellucci, A, Zotti, N, Fornaro, M, Gillman, K, Cattaneo, C I, van den Eynde, V, Birkenhager, T K, Ruhé, H G, Stahl, S, Iasevoli, F & de Bartolomeis, A 2023, ' Efficacy and safety of selegiline across different psychiatric disorders : A systematic review and meta-analysis of oral and transdermal formulations ', European Neuropsychopharmacology, vol. 72, pp. 60-78 . https://doi.org/10.1016/j.euroneuro.2023.03.012
European Neuropsychopharmacology, 72, 60-78
European Neuropsychopharmacology, 72, pp. 60-78

Selegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation) result-ing in non-selective MAOI activity at oral doses >20 mg/day. The pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::469fbb9eec6ee8b1011410740b411049
https://doi.org/10.1016/j.euroneuro.2023.03.012